The ATL1 antibody targets Atlastin-1. a protein encoded by the *ATL1* gene, which belongs to the dynamin family of GTPases. Atlastin-1 plays a critical role in endoplasmic reticulum (ER) membrane fusion, facilitating the formation of the ER's tubular network. Mutations in *ATL1* are linked to hereditary spastic paraplegia (HSP) type SPG3A, a neurodegenerative disorder characterized by progressive lower-limb spasticity and weakness due to axon degeneration in corticospinal tracts. ATL1 antibodies are widely used in research to study the protein's expression, localization, and function in cellular models, as well as to investigate disease mechanisms in HSP. These antibodies are employed in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to assess Atlastin-1 levels in tissues or cultured cells. Studies using ATL1 antibodies have contributed to understanding ER dynamics, vesicle trafficking, and neuronal maintenance. Additionally, they aid in exploring how *ATL1* mutations disrupt ER morphology and GTPase activity, leading to axonal defects. The antibody serves as a vital tool for validating disease models and potential therapeutic strategies targeting ER-associated pathways in neurodegenerative diseases.